Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
The following term was not found in PubMed: of
Page 1
Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Can Fam Physician. 2016 Jan;62(1):32-7.
Can Fam Physician. 2016.
PMID: 26796832
Free PMC article.
Review.
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of randomized controlled trials), level II (observational study), or level III (expert opinion). The best available evidence is mostly level …
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of rando …
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
Gouni-Berthold I, Descamps OS, Fraass U, Hartfield E, Allcott K, Dent R, März W.
Gouni-Berthold I, et al.
Br J Clin Pharmacol. 2016 Dec;82(6):1412-1443. doi: 10.1111/bcp.13066. Epub 2016 Oct 4.
Br J Clin Pharmacol. 2016.
PMID: 27478094
Free PMC article.
Review.
AIMS: Two anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been approved for the treatment of hypercholesterolaemia in certain patients. ...Both antibodies were effective and well tolerated across a broad pop …
AIMS: Two anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been appr …
Item in Clipboard
Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W, Qiang F, Peng W, Qian Z, Ke Z, Yi L, Jian Z, Chongrong Q.
Peng W, et al.
Int J Cardiol. 2016 Nov 1;222:119-129. doi: 10.1016/j.ijcard.2016.07.239. Epub 2016 Jul 30.
Int J Cardiol. 2016.
PMID: 27494723
Review.
The primary choice of therapy for controlling lipidemia has been statins, which are not completely effective. Proprotein convertase subtilisin/kexin type-9 (PCSK9), which interferes with LDL clearance from circulation, inversely relates to the LDL-C levels. ...
The primary choice of therapy for controlling lipidemia has been statins, which are not completely effective. Proprotein convertase subtilis …
Item in Clipboard
Cite
Cite